Loading stock data…
Krystal Biotech, Inc. (KRYS)
$351.26-6.98 (-1.95%)
Market ClosedLast close Sep 8
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Krystal Biotech, Inc. in the Healthcare sector is trading at $351.26 with a market capitalization of $9.8B. Wall Street consensus targets $385.00 (8 analysts), implying a +9.6% move over the next 12 months. The stock is currently near its 52-week high of $382.54, remaining 20.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +9.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $119.22M↑ | $116.36M↑ | $107.11M↑ | $97.80M↑ | $96.04M |
| Gross Profit | $112.78M↑ | $110.03M↑ | $100.51M↑ | $93.54M↑ | $88.88M |
| Operating Income | $58.42M↑ | $53.69M↑ | $44.27M↑ | $41.37M↑ | $39.40M |
| Net Income | $54.77M↓ | $55.93M↑ | $51.40M↓ | $79.36M↑ | $38.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremag...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.83B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
41.17
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.77%
Volume
Today's trading volume
255,600
Recent News
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says
Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blis
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More
Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.